CalciMedica, Inc. (CALC): Entry into a Material Definitive Agreement
CalciMedica, Inc. (CALC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.3 4 d40651dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
How this was made
The 30-second read
Why it matters
A warrant with a fixed exercise price and share quantity can affect valuation through potential dilution and by indicating the company’s financing structure/capital needs. However, the excerpt alone does not quantify total proceeds or immediate draw timing.
Market read
Traders can use the disclosed warrant economics (1,000,000 shares; $1.00 per share; expiration June 23, 2031) to reassess dilution over the facility’s life and potential overhang.
What to watch
Traders should verify the full 8-K exhibits for the loan size, draw schedule, maturity, and any covenants—those details determine whether dilution risk is immediate or deferred.
Background
The SEC filing is an 8-K (Item 1.01 and 3.02) that includes a warrant certificate issued in connection with a Loan and Security Agreement dated Feb. 28, 2025 (as amended).
Ticker impact
CalciMedica filed an 8-K disclosing a material definitive agreement tied to a warrant to purchase 1,000,000 shares at $1.00 per share.
Near-term price reaction is likely muted unless the broader financing terms (loan size, conversion mechanics, and any funding draw schedule) imply immediate cash needs or dilution risk.
The 8-K confirms a new, company-specific financing instrument (warrant) with explicit economics (1,000,000 shares; $1.00 exercise price) but the excerpt does not provide the total capital raised or immediate funding timing, limiting conviction on magnitude.
Market effects
Adds incremental financing/dilution risk signal for small-cap biotech/healthcare issuers that rely on structured debt/warrant facilities.
No clear regional spillover beyond US small-cap credit/financing sentiment.
Limited; this is company-specific and not tied to global macro or cross-border transactions.
Counterpoint
If the warrant is part of a larger facility already expected by the market, the incremental disclosure may be largely technical and not materially change near-term funding expectations.
Key entities
- companyCalciMedica, Inc.
US-listed issuer filing the 8-K and issuing the warrant.
- counterpartyAvenue Venture Opportunities Fund II, L.P.
Warrant holder/lender under the referenced Loan and Security Agreement.
- venueNasdaq Capital Market
Stated principal trading market for CalciMedica common stock.
